BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jeuring SFG, Biemans VBC, van den Heuvel TRA, Zeegers MP, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Masclee AAM, Jonkers DMAE, Pierik MJ. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era—Results from the Dutch Population-Based IBDSL Cohort. American Journal of Gastroenterology 2018;113:384-95. [DOI: 10.1038/ajg.2017.482] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Seow CH, Coward S, Kroeker KI, Stach J, Devitt KS, Targownik LE, Nguyen GC, Ma C, deBruyn JC, Carroll MW, Peerani F, Baumgart DC, Ryan DJ, Veldhuyzen van Zanten S, Benchimol EI, Kaplan GG, Panaccione R. Declining Corticosteroid Use for Inflammatory Bowel Disease Across Alberta: A Population-Based Cohort Study. Journal of the Canadian Association of Gastroenterology 2022. [DOI: 10.1093/jcag/gwac021] [Reference Citation Analysis]
2 Lerang F, Holst R, Henriksen M, Wåhlberg H, Jelsness-jørgensen L. Antitumour necrosis factor alpha treatment in Crohn’s disease: long-term efficacy, side effects and need for surgery. Scandinavian Journal of Gastroenterology. [DOI: 10.1080/00365521.2022.2042592] [Reference Citation Analysis]
3 Zhao M, Sall Jensen M, Knudsen T, Kelsen J, Coskun M, Kjellberg J, Burisch J. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study. Aliment Pharmacol Ther 2021. [PMID: 34881439 DOI: 10.1111/apt.16723] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
4 Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease. J Crohns Colitis. 2020;14:1316-1329. [PMID: 32170314 DOI: 10.1093/ecco-jcc/jjaa053] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 24.0] [Reference Citation Analysis]
5 Abdalla MI, Levesque BG. Progress in Corticosteroid Use in the Era of Biologics With Room for Improvement. Am J Gastroenterol 2021;116:1187-8. [PMID: 33840728 DOI: 10.14309/ajg.0000000000001261] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Goran L, State M, Negreanu A, Negreanu L. Quality of Care in Inflammatory Bowel Disease: the Role of Steroid Assessment Tool (SAT) - a Review. Rev Med Mod 2020;27:171-176. [DOI: 10.31689/rmm.2020.27.3.171] [Reference Citation Analysis]
7 Liu Z, Liu F, Wang W, Sun C, Gao D, Ma J, Hussain MA, Xu C, Jiang Z, Hou J. Study of the alleviation effects of a combination of Lactobacillus rhamnosus and inulin on mice with colitis. Food Funct 2020;11:3823-37. [PMID: 32329478 DOI: 10.1039/c9fo02992c] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 17.5] [Reference Citation Analysis]
8 Selinger CP, Parkes GC, Bassi A, Limdi JK, Ludlow H, Patel P, Smith M, Saluke S, Ndlovu Z, George B, Saunders J, Adamson M, Fraser A, Robinson J, Donovan F, Parisi I, Tidbury J, Gray L, Pollok R, Scott G, Raine T. Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients. Aliment Pharmacol Ther. 2019;50:1009-1018. [PMID: 31595533 DOI: 10.1111/apt.15497] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
9 Choi YI, Kim TJ, Park DK, Chung JW, Kim KO, Kwon KA, Kim YJ. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease. Int J Colorectal Dis. 2019;34:1713-1721. [PMID: 31471699 DOI: 10.1007/s00384-019-03368-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]